--- title: "Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MIRM Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/292526147.md" description: "Mirum Pharmaceuticals announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On July 10, 2026, the Compensation Committee granted non-qualified stock options for 6,300 shares and 9,300 RSUs to six new employees. Options vest over four years at an exercise price of $122.13, while RSUs vest over three years." datetime: "2026-07-13T12:01:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292526147.md) - [en](https://longbridge.com/en/news/292526147.md) - [zh-HK](https://longbridge.com/zh-HK/news/292526147.md) --- # Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MIRM Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 6,300 shares of common stock and 9,300 restricted stock units (“RSUs”) to 6 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $122.13 per share, which is equal to the closing price of Mirum’s common stock on July 10, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date, and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable initial vesting date, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. **About Mirum Pharmaceuticals** Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X. _Mirum and the Mirum logo are trademarks of Mirum Pharmaceuticals, Inc._ View source version on businesswire.com: https://www.businesswire.com/news/home/20260713219286/en/ **Investor Contact:** Andrew McKibben ir@mirumpharma.com **Media Contact:** Meredith Kiernan media@mirumpharma.com Source: Mirum Pharmaceuticals, Inc. ### Related Stocks - [MIRM.US](https://longbridge.com/en/quote/MIRM.US.md) ## Related News & Research - [Mirum Pharmaceuticals Q2 sales rise, lifts outlook](https://longbridge.com/en/news/295007489.md) - [The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM](https://longbridge.com/en/news/295203729.md) - [Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ARWR Stock News](https://longbridge.com/en/news/294737263.md) - [Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) | DNTH Stock News](https://longbridge.com/en/news/294743013.md) - [Mirum SVP, Global Controller Jolanda Howe sells 1,840 shares for $193,733.6](https://longbridge.com/en/news/295010149.md)